Skip to main content

Day: February 8, 2024

Phillips Edison & Company Reports Fourth Quarter and Full Year 2023 Results; Increases 2024 Guidance

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

CINCINNATI, Feb. 08, 2024 (GLOBE NEWSWIRE) — Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of grocery-anchored neighborhood shopping centers, today reported financial and operating results for the period ended December 31, 2023 and increased full year 2024 earnings guidance. For the fourth quarter and year ended December 31, 2023, net income attributable to stockholders was $13.5 million, or $0.11 per diluted share, and $56.8 million, or $0.48 per diluted share, respectively. Highlights for the Fourth Quarter Ended December 31, 2023Reported Nareit FFO of $74.8 million, or $0.56 per diluted share, representing 6.0% year-over-year growth Reported Core FFO of $77.9 million, or $0.58 per diluted share, representing 4.9% year-over-year growth Increased...

Continue reading

ESCO Reports First Quarter Fiscal 2024 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

– Q1 Sales increase 6% to $218 Million – $294 Million in Q1 Orders / Book-to-bill of 1.35x – Q1 GAAP EPS $0.59 / Adjusted EPS $0.62 – St. Louis, Feb. 08, 2024 (GLOBE NEWSWIRE) — ESCO Technologies Inc. (NYSE: ESE) (ESCO, or the Company) today reported its operating results for the first quarter ended December 31, 2023 (Q1 2024). Operating HighlightsQ1 2024 Sales increased $12.8 million (6.2 percent) to $218.3 million compared to $205.5 million in Q1 2023. Q1 2024 Entered Orders increased $64.8 million (28 percent) over the prior year period to $293.7 million (book-to-bill of 1.35x), resulting in record backlog of $848 million. Q1 2024 GAAP EPS increased 4 percent to $0.59 per share compared to $0.57 per share in Q1 2023. Q1 2024 Adjusted EPS increased 3 percent to $0.62 per share compared to $0.60 per share...

Continue reading

Regency Centers Reports Fourth Quarter and Full Year 2023 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

JACKSONVILLE, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) — Regency Centers Corporation (“Regency Centers”, “Regency” or the “Company”) (Nasdaq: REG) today reported financial and operating results for the period ended December 31, 2023. For the three months ended December 31, 2023 and 2022, Net Income was $0.47 per diluted share and $0.56 per diluted share, respectively. For the twelve months ended December 31, 2023 and 2022, Net Income was $2.04 per diluted share and $2.81 per diluted share, respectively. Fourth Quarter and Full Year 2023 HighlightsReported Nareit FFO of $1.02 per diluted share for the fourth quarter, and $4.15 per diluted share for the full year, including the impact of merger transition expense of $0.02 per diluted share and $0.03 per diluted share, respectively Reported Core Operating Earnings of $0.99 per diluted...

Continue reading

Seneca Foods Reports Sales and Earnings for the Quarter and Nine Months Ended December 30, 2023

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

FAIRPORT, N.Y., Feb. 08, 2024 (GLOBE NEWSWIRE) — Seneca Foods Corporation (NASDAQ: SENEA, SENEB) today announced financial results for the third quarter and nine months ended December 30, 2023. Executive Summary (vs. year-ago, year-to-date results):Net sales for the nine months ended December 30, 2023 totaled $1,150.6 million compared to $1,178.3 million for the nine months ended December 31, 2022. The year-over-year decrease of $27.7 million was mainly due to lower sales volumes partially offset by higher selling prices.Gross margin as a percentage of net sales for the nine months ended December 30, 2023 is 14.6% as compared to 10.0% for the nine months ended December 31, 2022.Reported net earnings were $65.6 million and $42.3 million for the nine months ended December 30, 2023 and December 31, 2022, respectively.“Third...

Continue reading

Sunergy Reports Third Quarter and First Nine Months 2023 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Net Revenue for the First Nine Months 2023 Increased 31% to $86.7 Million Amended Terms of Business Combination Agreement with ESGEN Acquisition Corp. Position the Combined Company for Growth Once Publicly Listed on Nasdaq DALLAS and NEW PORT RICHEY, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) — Sunergy Renewables, LLC (“Sunergy” or the “Company”), a leading Florida-based provider of residential solar and energy efficiency solutions, today reported financial results for the third quarter and nine months ended September 30, 2023. Recent Financial and Operational HighlightsNet revenue for the first nine months of 2023 increased 31% to $86.7 million Gross profit for the first nine months of 2023 increased 30% to $17.1 million Adjusted EBITDA for the first nine months of 2023 increased 12% to $9.9 million Solar system installations for...

Continue reading

Alpine Income Property Trust Reports Fourth Quarter and Full Year 2023 Operating Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

WINTER PARK, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company” or “PINE”) today announced its operating results and earnings for the quarter and year ended December 31, 2023. Select Full Year 2023 HighlightsReported Net Income per diluted share attributable to the Company of $0.19 for the year ended December 31, 2023. Reported FFO per diluted share of $1.47 for the year ended December 31, 2023. Reported AFFO per diluted share of $1.49 for the year ended December 31, 2023. Acquired 14 net lease properties for total acquisition volume of $82.9 million at a weighted average going-in cash cap rate of 7.4%. Originated three first mortgage investments totaling $38.6 million of funding commitments at a weighted average initial yield of 9.1%. Sold 24 net lease properties for total disposition...

Continue reading

NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13

Written by Customer Service on . Posted in Public Companies.

EDEN PRAIRIE, Minn., Feb. 08, 2024 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on February 13, 2024 at 4:30 PM Eastern Time to discuss financial results for its first quarter of fiscal year 2024 ended December 31, 2023, and provide a corporate update. Conference Call and Webcast Information: Tuesday, February 13, 2024 – 4:30 PM Eastern Time Participant Dial-In:888-506-0062 / +1 973-528-0011 Access Code: 540724 Live Webcast: Join here.         Phone Replay: 877-481-4010/ +1 919-882-2331Available through February 27, 2024 Webcast Replay:        Available for 12 months About...

Continue reading

Groupe Casino: Group Casino announces that it has reached agreements with Carrefour for the sale of 25 Casino hypermarkets and supermarkets

Written by Customer Service on . Posted in Public Companies.

Group Casino announces that it has reached agreements with Carrefour for the sale of 25 Casino hypermarkets and supermarkets Paris, 8 February 2024 Pursuant to the memorandum of understanding entered into with Groupement Les Mousquetaires on 24 January 20241, Groupement Les Mousquetaires has substituted Carrefour for the acquisition of some stores that were initially supposed to be acquired by Groupement Les Mousquetaires. In this context, Casino and Carrefour have entered into agreements2 providing for the sale of 25 stores (and the service stations attached to the stores) to Carrefour. Carrefour has undertaken similar employee commitments to those of Groupement Les Mousquetaires towards the employees assigned to the transferred stores and service stations. The disposals will take place on 30 April 2024, after consultation with the relevant...

Continue reading

Millicom (Tigo) notice of fourth quarter 2023 results and video conference

Written by Customer Service on . Posted in Public Companies.

Millicom (Tigo) notice of fourth quarter 2023 results and video conference Luxembourg, February 8, 2024 – Millicom expects to announce its fourth quarter 2023 results on February 27, 2024 via a press release. Millicom is planning to host a video conference for the global financial community on February 27, 2024 at 14:00 (Stockholm) / 13:00 (London) / 08:00 (Miami). Registration for the interactive event is required at the following link. After registering, you will receive a confirmation email containing details about joining the video conference. Participants who wish to ask a question during the live event must notify the Investor Relations team via email to investors@millicom.com after the start of the event. Participants may also join the conference in listen-only mode by dialing any of the following numbers and entering the Webinar...

Continue reading

Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members

Written by Customer Service on . Posted in Public Companies.

Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). In the original press release, it was incorrectly stated that the PALI-2108 development program was on track to commence a Phase 1 clinical study next year. The Company reiterates its guidance that the PALI-2108 Phase 1 clinical study is on track to launch in 2024. About Palisade Bio Palisade Bio is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.